UNSPSC 51172439: Bismuth hydroxide/kaolin/opium/pectin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.

UNSPSC 51172439 Bismuth hydroxide/kaolin/opium/pectin is a Commodity code that shows little relevant recent activity under its nominal scope. The three most recent state and local opportunities tagged to this code involve offender drug testing services (Collin County Community Supervision and Corrections Department), therapeutic pharmacy initiatives and direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations align with the antacid and antidiarrheal chemical compounds the code nominally describes. The mismatch suggests either systematic miscoding in state and local procurement systems or that the code is being applied to pharmaceutical procurement activity broadly rather than to the specific bismuth-based formulations the UNSPSC taxonomy intends.

The issuing bodies span a county criminal justice agency, a state health commission, and a multi-state cooperative administered by a state department of administration. Geographic spread includes Texas (two opportunities) and Minnesota/multi-state (one opportunity). The Collin County RFP for offender specimen collection and drug testing services, due July 23, 2026, estimates $600,000 annually and requires SAMHSA or state laboratory certification. The Minnesota Multistate Cooperative Purchasing Alliance RFP for generic pharmaceuticals and OTC products, due March 26, 2026, awards to multiple vendors through three authorized wholesalers with contracts effective July 1, 2026. The Texas HHS Commission's RFI on direct-to-manufacturer prescriptions, posted March 27, 2026, functions as market intelligence gathering rather than a formal solicitation. Firms treating this code as a pathway to pharmaceutical or laboratory testing opportunities rather than bismuth-based antacid compounds should verify actual scope alignment with the issuing body before pursuing.